LONDON (Reuters) - The GAVI global vaccine alliance said on Friday some 300,000 emergency doses of an Ebola vaccine developed by Merck could be available in case of a large-scale outbreak, after the World Health Organization confirmed a fatal case in Congo.
The vaccine, known as rVSV-ZEBOV, was shown to be highly protective against Ebola in clinical trials published last December.
A spokesman for the World Health Organization told Reuters on Friday that a person in the Democratic Republic of Congo had died after becoming infected with Ebola - a contagious virus that causes hemorrhagic fever.
Reporting by Kate Kelland; Editing by Hugh Lawson
Our Standards: The Thomson Reuters Trust Principles.